GlassScriptPhysician profile
Merle A Filecia
NPI 1447389804
$2,840.82
in general payments reported to CMS, 2019-2025
26 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $646 · 2023: $613 · 2024: $321 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $309.94 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $250.21 | 2021-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $246.34 | 2021-2022 | |
| Lilly USA, LLC | $225.61 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $187.58 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $120.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.91 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.19 | 2021-2022 | |
| Astellas Pharma US INC | $84.39 | 2023-2025 | Veozah |
| Abbvie INC. | $62.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.84 | 2021-2024 | Jardiance |
| Mannkind Corporation | $46.38 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $43.21 | 2021-2025 | Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.39 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.65 | 2025 | Korlym |
| Viatris Specialty LLC | $38.80 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $32.19 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $29.48 | 2021-2023 | Keveyis |
| Glaxosmithkline, LLC. | $23.46 | 2021-2022 | |
| Exact Sciences Corporation | $18.53 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $17.16 | 2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $16.75 | 2021 | |
| Axsome Therapeutics, INC. | $16.18 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $14.43 | 2025 | Nuzyra |
| Jazz Pharmaceuticals INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merle Filecia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.